TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Group Chairs: Research In “Crisis” ASCO Says NCTN Budgets Cut By 40 Percent, Warns of “Dangerous Disruption of Cancer Care” April 4, 2014